A Phase I Study of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified γδ T Cells in Patients With Newly Diagnosed Glioblastoma Multiforme Receiving Maintenance Temozolomide Chemotherapy
Latest Information Update: 10 Sep 2024
At a glance
- Drugs INB-200 (Primary) ; Temozolomide; Temozolomide; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- 04 Sep 2024 According to an IN8bio media release, the Company will suspend its glioblastoma (GBM) development program while continuing to monitor patients in the Phase 1 INB-200 clinical trial and those enrolled in the Phase 2 INB-400 clinical trial, will continue to monitor patients for long-term remissions and overall survival in both INB-400 and INB-200 at UAB.
- 12 Aug 2024 According to an IN8bio media release, updated clinical data from this trial is expected to be presented in Q4 2024.
- 04 Jun 2024 Results (n=15) assessing the safety of single and multiple infusions of autologous CRCT cells presents updated safety and efficacy data, presented at the 60th Annual Meeting of the American Society of Clinical Oncology